



**Contact:**

Douglas Doerfler  
Chief Executive Officer  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte Appoints Ronald Holtz as Chief Financial Officer**

**Gaithersburg, MD, April 26, 2005** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced today that it has appointed Ronald Holtz as Chief Financial Officer.

Douglas A Doerfler, President and CEO of MaxCyte commented, "We are excited to have Ron join MaxCyte and solidify our senior leadership team. Ron's experience and insights are critical as we enter our next stage of growth."

"I am pleased to join the MaxCyte team at an exciting time in its development. The Company has assembled a powerful scientific and business team in its staff and advisors and is well positioned to leverage its industry leading cell loading and gene delivery technologies. I look forward to contributing to MaxCyte's future success," stated Ron Holtz.

Prior to joining MaxCyte, Mr. Holtz was Chief Financial Officer of B2eMarkets, Inc. a privately held software solutions company targeting Global 1000 companies. Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies, Inc., a leading information technology and performance improvement consulting firm. During his career, Mr. Holtz has been CFO of both public and private companies and has raised more than \$100m in debt and equity capital. Mr. Holtz is also a founding member of the Robert H. Smith School of Business Finance Advisory Board at the University of Maryland. He earned a master's of business administration in finance from the University of Maryland, a bachelor's of science degree in mathematics from the University of Wisconsin and is a CPA.

**About MaxCyte**

MaxCyte is a clinical stage therapeutics company developing both proprietary and partnered therapeutics. The company's mission is to use its proprietary cell-loading technology to advance its therapeutic programs and enable other developers of *ex vivo* cell therapies and manufacturers of biopharmaceutical products and therapies. MaxCyte's strength is its ability to accelerate development timelines and reduce risk in bringing cell and gene therapies from bench to a clinical reality. MaxCyte's proprietary cell loading technology is closed and scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary, infectious and genetic disease, and oncology. MaxCyte's technology for biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-clinical through clinical trials and through to product manufacturing. Cell-loading technologies are

fundamental to cell-based therapeutics, gene therapy, and many biopharmaceutical manufacturing applications. MaxCyte has developed and commercialized the most efficient non-viral, clinical grade, scalable, GMP-compliant cell-loading technology in the marketplace.

For more information, visit <http://www.maxcyte.com>.

*This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.*

###